|
1
|
Shukla SK, Singh G, Shahi KS, Bhuvan and
Pant P: Staging, treatment, and future approaches of gallbladder
carcinoma. J Gastrointest Cancer. 49:9–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cervello M, Augello G, Cusimano A, Emma
MR, Balasus D, Azzolina A, McCubrey JA and Montalto G: Pivotal
roles of glycogen synthase-3 in hepatocellular carcinoma. Adv Biol
Regul. 65:59–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kang KJ and Ahn KS: Anatomical resection
of hepatocellular carcinoma: A critical review of the procedure and
its benefits on survival. World J Gastroenterol. 23:1139–1146.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: how intimate is the relationship? Ann NY Acad Sci 1171.
59–76. 2009. View Article : Google Scholar
|
|
5
|
Calvisi DF, Ladu S, Gorden A, Farina M,
Conner EA, Lee JS, Factor VM and Thorgeirsson SS: Ubiquitous
activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barre B, Avril S and Coqueret O: Opposite
regulation of myc and p21waf1 transcription by STAT3 proteins. J
Biol Chem. 278:2990–2996. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang HY, Cheng Z and Malbon CC:
Overexpression of mitogen-activated protein kinase phosphatases
MKP1, MKP2 in human breast cancer. Cancer Lett. 191:229–237. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson FM, Saigal B, Tran H and Donato
NJ: Abrogation of signal transducer and activator of transcription
3 reactivation after Src kinase inhibition results in synergistic
antitumor effects. Clin Cancer Res. 13:4233–4244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oh SB, Hwang CJ, Song SY, Jung YY, Yun HM,
Sok CH, Sung HC, Yi JM, Park DH, Ham YW, et al: Anti-cancer effect
of tectochrysin in NSCLC cells through overexpression of death
receptor and inactivation of STAT3. Cancer Lett. 353:95–103. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carie AE and Sebti SM: A chemical biology
approach identifies a beta-2 adrenergic receptor agonist that
causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2
pathway. Oncogene. 26:3777–3788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moeller G and Adamski J:
Multifunctionality of human 17beta-hydroxysteroid dehydrogenases.
Mol Cell Endocrinol. 248:47–55. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peltoketo H, Luu-The V, Simard J and
Adamski J: 17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid
reductase (KSR) family; nomenclature and main characteristics of
the 17HSD/KSR enzymes. J Mol Endocrinol. 23:1–11. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Markus M, Husen B, Leenders F, Jungblut
PW, Hall PF and Adamski J: The organelles containing porcine 17
beta-estradiol dehydrogenase are peroxisomes. Eur J Cell Biol.
68:263–267. 1995.PubMed/NCBI
|
|
14
|
Rasiah KK, Gardiner-Garden M, Padilla EJ,
Möller G, Kench JG, Alles MC, Eggleton SA, Stricker PD, Adamski J
and Sutherland RL: HSD17B4 overexpression, an independent biomarker
of poor patient outcome in prostate cancer. Mol Cell Endocrinol.
301:89–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maleki J, Nourbakhsh M, Shabani M, Korani
M, Nourazarian SM, Ostadali DM and Moghadasi MH: 17β-estradiol
stimulates generation of reactive species oxygen and nitric oxide
in ovarian adenocarcinoma cells (OVCAR 3). Iran J Cancer Prev.
8:e23322015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu X, Ma P, Shi Y, Yao M, Hou L, Zhang P
and Jiang L: NF-κB increased expression of 17beta-hydroxysteroid
dehydrogenase 4 promotes HepG2 proliferation via inactivating
estradiol. Mol Cell Endocrinol. 401:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim NH, Heo JD, Kim TB, Rho JR, Yang MH
and Jeong EJ: Protective effects of ethyl acetate soluble fraction
of Limonium tetragonum on diethylnitrosamine-induced liver
fibrosis in rats. Biol Pharm Bull. 39:1022–1028. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bookout AL and Mangelsdorf DJ:
Quantitative real-time PCR protocol for analysis of nuclear
receptor signaling pathways. Nucl Recept Signal. 1:e0122003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fishbein MC, Wang T, Matijasevic M, Hong L
and Apple FS: Myocardial tissue troponins T and I. An
immunohistochemical study in experimental models of myocardial
ischemia. Cardiovasc Pathol. 12:65–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia H, Li Y, Zhao T, Li X, Hu J, Yin D,
Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of
Stat3-siRNA and endostatin combined therapies, delivered by
attenuated Salmonella, on orthotopically implanted hepatocarcinoma.
Cancer Immunol Immunother. 61:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fang L, Li G, Liu G, Lee SW and Aaronson
SA: p53 induction of heparin-binding EGF-like growth factor
counteracts p53 growth suppression through activation of MAPK and
PI3K/Akt signaling cascades. EMBO J. 20:1931–1939. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Breitling R, Marijanovic Z, Perovic D and
Adamski J: Evolution of 17beta-HSD type 4, a multifunctional
protein of beta-oxidation. Mol Cell Endocrinol. 171:205–210. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Launoit Y and Adamski J: Unique
multifunctional HSD17B4 gene product: 17beta-hydroxysteroid
dehydrogenase 4 and D-3-hydroxyacyl-coenzyme A
dehydrogenase/hydratase involved in Zellweger syndrome. J Mol
Endocrinol. 22:227–240. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Veldhoven PP, Casteels M, Mannaerts GP and
Baes M: Further insights into peroxisomal lipid breakdown via
alpha- and beta-oxidation. Biochem Soc Trans. 29:292–298. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Romanuik TL, Wang G, Morozova O, Delaney
A, Marra MA and Sadar MD: LNCaP Atlas: Gene expression associated
with in vivo progression to castrationrecurrent prostate cancer.
BMC Med. Genomics. 3:432010.
|
|
27
|
True L, Coleman I, Hawley S, Huang CY,
Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, et
al: A molecular correlate to the Gleason grading system for
prostate adenocarcinoma. Proc Natl Acad Sci USA. 103:10991–10996.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zha S, Ferdinandusse S, Hicks JL, Denis S,
Dunn TA, Wanders RJ, Luo J, De Marzo AM and Isaacs WB: 2005.
Peroxisomal branched chain fatty acid beta-oxidation pathway is
upregulated in prostate cancer. Prostate. 63:316–323. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ihle JN: STATs: Signal transducers and
activators of transcription. Cell. 84:331–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Costantino L and Barlocco D: STAT 3 as a
target for cancer drug discovery. Curr Med Chem. 15:834–843. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aggarwal BB, Sethi G, Ahn KS, Sandur SK,
Pandey MK, Kunnumakkara AB, Sung B and Ichikawa H: Targeting
signal- transducer-and-activator-of-transcription-3 for prevention
and therapy of cancer: Modern target but ancient solution. Ann NY
Acad Sci 1091. 151–169. 2006. View Article : Google Scholar
|
|
32
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK,
Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, et
al: Potential role of signal transducer and activator of
transcription (STAT)3 signaling pathway in inflammation, survival,
proliferation and invasion of hepatocellular carcinoma. Biochim
Biophys Acta 1835. 46–60. 2013.
|
|
33
|
Subramaniam A, Shanmugam MK, Ong TH, Li F,
Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, et al:
Emodin inhibits growth and induces apoptosis in an orthotopic
hepatocellular carcinoma model by blocking activation of STAT3. Br
J Pharmacol. 170:807–821. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schindler C and Darnell JE Jr:
Transcriptional responses to polypeptide ligands: the JAK-STAT
pathway. Annu Rev Biochem. 64:621–651. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chiarle R, Simmons WJ, Cai H, Dhall G,
Zamo A, Raz R, Karras JG, Levy DE and Inghirami G: Stat3 is
required for ALK-mediated lymphomagenesis and provides a possible
therapeutic target. Nat Med. 11:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schuringa JJ, Jonk LJ, Dokter WH, Vellenga
E and Kruijer W: Interleukin-6-induced STAT3 transactivation and
Ser727 phosphorylation involves Vav, Rac-1 and the kinase
SEK-1/MKK-4 as signal transduction components. Biochem J 347 Pt.
1:89–96. 2000. View Article : Google Scholar
|
|
37
|
Gu FM, Li QL, Gao Q, Jiang JH, Huang XY,
Pan JF, Fan J and Zhou J: Sorafenib inhibits growth and metastasis
of hepatocellular carcinoma by blocking STAT3. World J
Gastroenterol. 17:3922–3932. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiablaem K, Lirdprapamongkol K,
Keeratichamroen S, Surarit R and Svasti J: Curcumin suppresses
vasculogenic mimicry capacity of hepatocellular carcinoma cells
through STAT3 and PI3K/AKT inhibition. Anticancer Res.
34:1857–1864. 2014.PubMed/NCBI
|
